Home / Health / FDA Backs New Drug Testing Methods
FDA Backs New Drug Testing Methods
18 Mar
Summary
- FDA issues draft guidance to reduce animal drug studies.
- New methods include computer simulations and organoids.
- Goal is more efficient, cheaper, and ethical drug development.
The U.S. Food and Drug Administration (FDA) released draft guidance on March 18, 2026, aimed at helping companies reduce their reliance on animal testing for experimental drugs. This initiative encourages the adoption of advanced methods, including computer simulations and organ-on-a-chip technologies that mimic human organ functions.
Traditional animal studies, often conducted on primates, have proven insufficient as many candidates that pass these tests still fail in human trials due to safety and efficacy concerns. The FDA's new approach methodologies (NAMs) include cell-based tests and 3D organoid models grown from human cells.
These scientifically rigorous, human-relevant methods are expected to streamline the drug development process, making it more efficient, less expensive, and more ethical. U.S. Health and Human Services Secretary Robert F. Kennedy Jr. stated this guidance advances the commitment to replace animal testing. The FDA believes this reform can accelerate drug market entry and reduce research and development costs, potentially leading to lower drug prices.
Separately, the National Institutes of Health announced a $150 million investment in human-based research to further decrease animal model usage. Drug developers are increasingly integrating artificial intelligence tools, which experts predict could halve development timelines and costs within three to five years.
